GC Wealth Management RIA LLC Lowers Stock Position in Stryker Corporation $SYK

01 May 2026, 06:03 by Amy Steele · The Cerbat Gem

GC Wealth Management RIA LLC reduced its stake in shares of Stryker Corporation (NYSE:SYK – Free Report) by 62.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,167 shares of the medical technology company’s stock after selling 3,530 shares during the period. GC Wealth Management RIA LLC’s holdings in Stryker were worth $762,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Venturi Wealth Management LLC lifted its position in shares of Stryker by 1.4% during the 3rd quarter. Venturi Wealth Management LLC now owns 1,904 shares of the medical technology company’s stock valued at $704,000 after buying an additional 27 shares in the last quarter. Wolff Wiese Magana LLC lifted its position in shares of Stryker by 2.3% during the 3rd quarter. Wolff Wiese Magana LLC now owns 1,271 shares of the medical technology company’s stock valued at $470,000 after buying an additional 28 shares in the last quarter. Lantz Financial LLC lifted its position in shares of Stryker by 5.0% during the 3rd quarter. Lantz Financial LLC now owns 608 shares of the medical technology company’s stock valued at $225,000 after buying an additional 29 shares in the last quarter. Stonebridge Capital Advisors LLC lifted its position in shares of Stryker by 0.4% during the 3rd quarter. Stonebridge Capital Advisors LLC now owns 7,198 shares of the medical technology company’s stock valued at $2,661,000 after buying an additional 29 shares in the last quarter. Finally, Tcfg Wealth Management LLC lifted its holdings in Stryker by 2.7% in the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after purchasing an additional 29 shares in the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on SYK. Needham & Company LLC boosted their price target on Stryker from $448.00 to $454.00 and gave the stock a “buy” rating in a report on Friday, January 30th. Jefferies Financial Group reissued a “buy” rating and issued a $465.00 price target on shares of Stryker in a report on Wednesday, March 4th. Robert W. Baird set a $437.00 price target on Stryker in a report on Friday, January 30th. Barclays reissued an “overweight” rating and issued a $469.00 price target on shares of Stryker in a report on Monday, February 2nd. Finally, William Blair reissued an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. Fifteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus price target of $421.11.

Get Our Latest Analysis on Stryker

Insider Activity

In other news, Director Ronda E. Stryker sold 250,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the sale, the director directly owned 2,457,331 shares of the company’s stock, valued at $891,814,566.52. This represents a 9.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.60% of the stock is owned by company insiders.

Trending Headlines about Stryker

Here are the key news stories impacting Stryker this week:

Positive Sentiment: Strong cash flow and profitability expansion — Reported net income, operating profit and cash from operations rose materially year-over-year (cash from ops jumped sharply), supporting balance-sheet strength and capital spending. Quiver Quantitative: Q1 results
Positive Sentiment: Company maintained FY‑2026 EPS guidance (14.900–15.100), signaling management confidence in full‑year recovery despite the soft quarter. Reuters: misses estimates, maintains outlook
Neutral Sentiment: Company highlighted quick operational recovery from a recent cyber incident; management framed the issue as contained and service delivery resumed. WSJ: cyberattack recovery
Neutral Sentiment: Ongoing commercial wins and government contract awards provide recurring revenue tailwinds, but these are modest relative to total sales. Quiver: gov’t contracts & institutional activity
Negative Sentiment: Earnings and revenue missed consensus — Q1 adjusted EPS missed estimates and revenue growth was only ~2.6%, below Street expectations, driving the initial negative market reaction. Zacks: EPS & revenue lag
Negative Sentiment: Demand weakness in implants and complex-procedure devices weighed on results and led to a contraction in adjusted operating margin (down ~180 bps) and lower adjusted EPS versus prior year. GlobeNewswire: operating results & margin details
Negative Sentiment: Insider and large institutional selling noted in filings and data feeds, which can add downward pressure on the stock in the near term. Quiver: insider & hedge fund activity

Stryker Stock Down 0.2%

NYSE SYK opened at $314.64 on Friday. The stock has a market cap of $120.50 billion, a PE ratio of 37.46, a P/E/G ratio of 1.84 and a beta of 0.92. Stryker Corporation has a 12 month low of $311.31 and a 12 month high of $404.87. The stock’s 50 day moving average is $345.67 and its 200 day moving average is $356.95. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The firm’s revenue was up 2.6% on a year-over-year basis. During the same period last year, the company earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Research analysts predict that Stryker Corporation will post 14.91 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend was Tuesday, March 31st. Stryker’s dividend payout ratio is 41.90%.

About Stryker

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Five stocks we like better than Stryker

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).